Valuation : Exact Sciences Corporation

Market Cap 2TCr 34TCr 1.73TCr 1.62TCr 1.48TCr 2.78TCr 1,91400Cr 2.79TCr 19TCr 7.49TCr 97TCr 7.52TCr 7.36TCr 3,20400Cr P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 2.16TCr 37TCr 1.86TCr 1.74TCr 1.59TCr 3TCr 2,06400Cr 3.01TCr 21TCr 8.08TCr 1,04200Cr 8.11TCr 7.93TCr 3,45500Cr EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
Change 5-day change 1-year change 3-year change Capi.($)
-15.23%+9.18% - - 2TCr
-4.73%-3.08%+91.12%+277.10% 402.02Cr
-3.03%-3.38%+259.19%+30.88% 362.83Cr
-4.22%+2.43%+42.85%+64.79% 348.41Cr
-4.91%+2.43%+264.49%+442.37% 257.58Cr
-3.09%-6.35%-26.54%-26.21% 225.47Cr
+6.10%+7.10%+39.80% - 158.91Cr
+11.76%+16.89%+37.38%+60.22% 117.84Cr
-8.24%-11.11%+217.36%-26.30% 114.42Cr
-2.87%+25.09%+27.90%+184.74% 68Cr
Average -2.85%+0.06%+105.95%+125.95% 228.34Cr
Weighted average by Cap. -8.80%-0.51%+119.33%+142.28%

Financials

2024 2025
Net sales 275.89Cr 4.7TCr 237.73Cr 222.9Cr 203.47Cr 383.31Cr 26TCr 384.53Cr 2.64TCr 1.03TCr 13TCr 1.04TCr 1.01TCr 44TCr 324.7Cr 5.53TCr 279.79Cr 262.33Cr 239.47Cr 451.13Cr 31TCr 452.57Cr 3.11TCr 1.21TCr 16TCr 1.22TCr 1.19TCr 52TCr
Net income -102.89Cr -1.75TCr -89Cr -83Cr -76Cr -142.95Cr -9.83TCr -143.4Cr -986.2Cr -384.78Cr -4.96TCr -386.28Cr -377.88Cr -16TCr -21Cr -354.22Cr -18Cr -17Cr -15Cr -29Cr -1.99TCr -29Cr -199.33Cr -78Cr -1TCr -78Cr -76Cr -3.33TCr
Net Debt 173.77Cr 2.96TCr 149.74Cr 140.4Cr 128.16Cr 241.43Cr 17TCr 242.2Cr 1.67TCr 649.89Cr 8.38TCr 652.43Cr 638.23Cr 28TCr 157.01Cr 2.67TCr 135.3Cr 126.85Cr 115.8Cr 218.15Cr 15TCr 218.84Cr 1.51TCr 587.21Cr 7.58TCr 589.5Cr 576.67Cr 25TCr
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. It offers a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. Its portfolio includes brands such as Cologuard and Oncotype DX, along with solutions like Cancerguard for blood-based analysis of molecular information across multiple cancers and Oncodetect for molecular residual disease and recurrence monitoring. Its flagship screening products, the Cologuard and Cologuard Plus tests, are patient-friendly, non-invasive, stool-based DNA (sDNA) screening tests that utilize a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its Cancerguard test is designed to detect multiple cancers in their earliest stages from a single blood draw. It offers predefined genetic tests for all clinically relevant genes, and whole genome (PGnome) sequencing tests.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA